Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

New England Journal of Medicine - Tập 379 Số 22 - Trang 2108-2121 - 2018
Thomas Powles1, Sylvia Adams2, Hope S. Rugo3, Andreas Schneeweiss4, Carlos H. Barrios5, Hiroji Iwata6, Véronique Dièras7, Roberto Hegg8, Seock‐Ah Im9, Gail S. Wright10, Volkmar Henschel11, Luciana Molinero12, Jane Yuet Ching Hui12, Roel Funke12, Amreen Husain11, Eric P. Winer13, Sherene Loi14, Leisha A. Emens15
1Barts Cancer Institute, Queen Mary University of London, London
2Perlmutter Cancer Center, New York University School of Medicine, New York
3Department of Medicine, University of California San Francisco, San Francisco
4University Hospital Heidelberg, Heidelberg, Germany
5Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre
6Aichi Cancer Center Hospital, Nagoya, Japan
7Department of Medical Oncology, Institut Curie, Paris
8University of São Paulo, São Paulo
9Seoul National University Hospital Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
10Florida Cancer Specialists and Research Institute, New Port Richey
11Roche, Basel, Switzerland
12Genentech, South San Francisco
13Dana Farber Cancer Institute, Boston
14Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Vic, Australia
15Bloomberg–Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1007/s10549-016-4080-9

10.1634/theoncologist.2014-0002

10.1093/annonc/mdy192

10.1093/annonc/mdv298

10.1016/j.ejca.2018.03.015

10.1093/annonc/mdy201

10.1093/annonc/mdt276

10.18632/oncotarget.3216

10.1158/2326-6066.CIR-13-0127

10.1016/j.immuni.2013.07.012

10.1038/nature14011

Tecentriq (atezolizumab): summary of product characteristics. Welwyn Garden City, United Kingdom: Roche Registration, 2018.

Tecentriq (atezolizumab). South San Francisco, CA: Genentech, 2018 (package insert).

10.1001/jamaoncol.2018.4224

10.1158/2326-6066.CIR-15-0064

10.2147/OTT.S122974

10.1200/JCO.2017.35.15_suppl.9092

10.1200/JCO.2018.36.18_suppl.LBA9000

10.1200/JCO.2013.50.9984

10.1200/JCO.2009.25.6529

10.1097/PAI.0000000000000594

10.1158/1538-7445.SABCS17-PD6-10

10.1007/s10549-017-4537-5

10.1056/NEJMoa1716948

10.1056/NEJMoa1801005

10.1200/JCO.2017.77.6385

10.1200/JCO.2011.41.0902

10.1200/JCO.2013.55.0491

10.1093/annonc/mdx440.005

10.1158/1538-7445.SABCS17-P2-09-13